Skip to content
2000
Volume 9, Issue 3
  • ISSN: 1574-8871
  • E-ISSN: 1876-1038

Abstract

Due to their high prevalence, non-alcoholic fatty liver disease (NAFLD), insulin resistance (IR) and hepatitis C virus (HCV) infection are bound to cohabit. However, the relationship between these 3 entities is complex and multilayered. HCV, particularly genotype 3, may induce a “viral” steatosis, morphologically indistinguishable from the steatosis of NAFLD but with different implications and prognosis. On the other hand, epidemiological and experimental data show that patients with HCV have a higher risk of developing IR and, in susceptible individuals, type 2 diabetes (T2D). In patients with HCV, T2D increases fibrosis progression rate, increases the incidence of HCC, worsens liver-related outcomes and worsens response to interferon-α based therapy. We conclude by discussing a possible increased incidence of cardiovascular events in HCV patients.

Loading

Article metrics loading...

/content/journals/rrct/10.2174/1574887109666141216101939
2014-09-01
2025-12-13
Loading full text...

Full text loading...

/content/journals/rrct/10.2174/1574887109666141216101939
Loading

  • Article Type:
    Research Article
Keyword(s): Fibrosis; hepatitis C virus; non-alcoholic fatty liver disease; steatosis
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test